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Abstract
Background—In adults, depressive symptoms are positively associated with insulin resistance.
Objective—To determine whether an association exists between depressive symptoms and
markers of insulin resistance in youth.
Methods—This study used a retrospective review of data from an obesity clinic. We evaluated
the association between depressive symptoms (Children's Depression Inventory, CDI) and fasting
insulin and homeostatic model assessment–insulin resistance (HOMA-IR) in obese youth (n=207,
age 10-18 years). Individuals with lower versus higher CDI T-scores (<65 vs ≥65) were compared;
this cut-point is accepted as indicating the possibility of clinical depression. Multiple linear
regression was used to evaluate relationships between CDI T-scores and insulin resistance.
Results—Fasting insulin and HOMA-IR values were 40% higher in patients with higher CDI T-
scores (p=0.04). After accounting for gender, race, age, and BMI, CDI T-score remained
associated with HOMA-IR, although the strength of the association was small (b=0.007, p=0.049).
Conclusions—Relationships between depressive symptoms and insulin resistance should be
considered when evaluating obese youth.
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In young adults, depressive symptoms are positively associated with insulin resistance (1).
Moreover, clinically depressed adults demonstrate insulin resistance, higher fasting glucose,
and are known to have greater risk for type 2 diabetes (2). Obese youth have prevalent
psychosocial stressors and insulin resistance associated with obesity (3). However, studies
evaluating whether depressive symptoms among obese youth are associated with even
greater insulin resistance are scarce. This is relevant, as increasing insulin resistance is
associated with the development of type 2 diabetes and inferior cardiometabolic risk
profiles. The knowledge of this association would aid clinical evaluation, as youth with
clinical depression may be at higher risk for developing glucose intolerance or type 2
diabetes. The objective of this study was to determine if an association exists between
depressive symptoms and fasting markers of insulin resistance in obese youth. We evaluated
relationships between depressive symptoms and biomarkers of insulin resistance in an obese
pediatric and adolescent clinic population. We hypothesized that depressive symptoms
would be positively associated with fasting insulin levels in obese youth, as has been shown
in adults.
Methods
We reviewed clinical data from all patients evaluated in the clinic at the Pediatric
Overweight Education and Research (POWER) Program at Riley Hospital for Children at
Indiana University Health between January 2009 and November 2011. A waiver of informed
consent was obtained from the Indiana University Institutional Review Board prior to
initiating the study. For the purposes of the POWER Clinic, obesity was defined as having a
body mass index ≥85th percentile for age and gender. The Children's Depression Inventory
(CDI) was used as a standard part of the clinical evaluation to assess depressive symptoms
(4). The CDI is a widely used measure comprised of 27 items loading on five primary
factors: negative mood, interpersonal problems, ineffectiveness, anhedonia, and negative
self-esteem. The total raw score from the CDI items is converted to a standardized T-score.
CDI T-scores are based on a normative sample of 1266 youths and are calculated based on
age and gender. Laboratory evaluation included fasting lipids, liver transaminases, glucose,
insulin, and hemoglobin A1c (HbA1c). Plasma glucose was measured using the glucose
hexokinase method (CV 2%). Plasma insulin was measured with chemiluminescent
sandwich assay (CV 6%). Fasting lipid profile was measured using the Beckman Coulter
DXC 800. Liver transaminases were assessed via spectrophotometry. HbA1c was measured
with the high-performance liquid chromatography method. The homeostasis model
assessment of insulin resistance (HOMA-IR) was calculated with fasting glucose and insulin
(5).
Patients treated for depression or other psychiatric conditions (n=45) or who had diabetes
(n=8) were excluded. This was a retrospective review of clinical data where Tanner stage
data was inconsistently available. Thus, we restricted the analysis to youth between the ages
of 10-18 years with complete data (n=207) to minimize the number of prepubertal children
in the analysis. Individuals with lower versus higher CDI T-scores (<65 vs ≥65) were
compared. This cut-point is accepted as useful for indicating the potential of clinical
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depression (4). The chi-square test for independence or the Fisher's exact probability test
was used to compare categorical variables. The Welch t-test, suitable for two groups with
unequal sample sizes and unequal variances, was used to compare continuous variables. We
evaluated whether CDI T-scores as a continuous variable were associated with markers of
insulin resistance while controlling for gender, race, age, and BMI Z-score with multiple
linear regression. R software was used to perform analyses. P-values <0.05 were considered
significant. This study was approved by the Indiana University Institutional Review Board.
Results
The characteristics of the patients are summarized in Table 1. The mean CDI T-score for the
study population was 48±11; median=46; range 34-100. CDI T-scores did not vary by
gender, race, or age. Markers of cardiometabolic risk and insulin sensitivity according to
CDI T-score group are shown in Table 2. There were no differences in anthropometric
measures, blood pressure, lipids, liver transaminases, HbA1c, or fasting glucose among the
groups. The mean fasting insulin and HOMA-IR values were 40% higher in the group with
higher CDI T-scores (p=0.03 and p=0.04) reflecting greater insulin resistance.
After controlling for the effects of gender, race, age, and BMI Z-score, CDI T-score
measured as a continuous variable remained associated with HOMA-IR (b=0.007, 95% CI
(0.00001, 0.014), adjusted R2=0.12, p=0.049). Hispanic race (b=0.438, p=0.007), female sex
(b=0.170, p=0.044), and BMI Z-score (b=0.560, p<0.001) were significantly associated with
greater insulin resistance.
Discussion
Currently, approximately 17% of U.S. adolescents are obese, as defined by having a BMI
greater than or equal to the 95th percentile for age and sex (6). Of this population, a
significant percentage has a combination of unfavorable risk factors for the development of
type 2 diabetes, including insulin resistance, which poses enormous public health
implications. In this study of a clinic population of 10-18 year-old obese youth, patients
meeting the CDI T-score cut-point indicating increased risk for depression had 40% higher
fasting insulin and HOMA-IR values than patients with CDI T-scores in the normal range.
After adjusting for gender, race, age, and BMI, CDI T-scores remained positively associated
with HOMA-IR values, although the strength of the association was small. These findings
suggest that obese youth with more depressive symptoms are insulin resistant compared
with those without depressive symptoms, independent of BMI. The relationships between
depressive symptoms and metabolic risk factors in obese youth are likely to be highly
relevant and potentially modifiable, which holds the promise of facilitating improvement in
the health care of obese youth and improving clinical outcomes. The findings here imply
that there is a need to implement systems to screen obese youth for depressive symptoms, in
addition to risk for type 2 diabetes, during routine clinical care. Moreover, additional
research is needed to determine the effectiveness of addressing depressive symptoms
(medically and/or via social support) to reduce risk factors for type 2 diabetes.
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Some studies have found depressive symptoms to be correlated with the degree of obesity
(7), while others have found an association between depressive symptoms and insulin
resistance after controlling for obesity in adolescents (8, 9). A prospective pediatric study
evaluated depressive symptoms and HOMA-IR at a baseline visit and again approximately 6
years later (10). Depressive symptoms at baseline predicted follow-up HOMA-IR,
independent of BMI. While the directionality of these relationships remains unclear, results
of this previous study suggest that the pathophysiology related to depressive symptoms
precedes the increase in fasting insulin. This implies that treating depressive symptoms in
youth might improve insulin sensitivity, which deserves further investigation.
This study was not designed to evaluate the mechanisms of this relationship, but the results
indicate need for studies examining factors linking depression and insulin resistance.
Previously proposed mechanistic pathways linking anxiety, emotional stress, and depressive
symptoms to adverse cardiometabolic risk factors include poor sleep (11), activation or
dysregulation of the hypothalamic–pituitary–adrenal axis leading to chronically increased
levels of catecholamines (12), and systemic inflammation and oxidative stress (13).
Advances in the understanding of insulin resistance and depression provide evidence that
shared inflammatory mechanisms may link these conditions biologically (14).
There were limitations associated with this retrospective review of clinical data.
Socioeconomic status data was not available for analysis. Most patients were insured but we
cannot rule-out an effect of socioeconomic status on the results. Moreover, these results are
not generalizable to non-obese individuals or to youth with previously diagnosed depression.
We had relatively few youth with CDI-T-scores ≥ 65, limiting the power to detect
differences between the two groups, and the study did not include repeated CDI
measurements over time. Finally, we did not adjust for the effect of puberty on insulin
sensitivity because Tanner stage data was inconsistently available. Age, BMI, and BMI Z-
score were remarkably similar between the two groups, which would be unlikely to occur if
the pubertal stage was significantly different in one of the two groups. Future studies should
also address race/ethnicity, as others have reported that depressed mood may be most
problematic among adolescent girls in the white racial/ethnic group (15).
In conclusion, youth referred for treatment of obesity who endorse more depressive
symptoms have markers indicating greater insulin resistance. Obese youth should be
screened for depression, along with diabetes risk factors (family history, acanthosis
nigricans, minority race/ethnicity, etc) to direct clinical care (16).
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Table 1
Patient Characteristics (n = 207)
CDI T-score < 65
(n = 192)
46 ± 8





 Male 68 (35%) 5 (33%)
0.91
 Female 124 (65%) 10 (67%)
Race, n (%)*
 White 97 (51%) 8 (53%)
0.66
 Black 75 (39%) 5 (33%)
 Hispanic 12 (6%) 1 (7%)
 Other 6 (3%) 1 (7%)
Age, y 13.5 ± 2.2 13.5 ± 1.9 0.93
BMI, kg/m2 38.3 ± 8.3 37.7 ± 6.7 0.78
BMI Z-score 2.49 ± 0.32 2.45 ± 0.20 0.63
Data are expressed as mean ± standard deviation unless otherwise indicated.
*
Race information was missing for 2 (1%) of patients.
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Table 2
Markers of Cardiometabolic Risk and Insulin Sensitivity According to Children's
Depressive Inventory T-Score Group
CDI T-score < 65
(n = 192)
46 ± 8





 Systolic 114.1 ± 12.8 107.5 ± 14.6 0.07
 Diastolic 70.3 ± 11.0 72.8 ± 9.3 0.41
Blood pressure, %ile
 Systolic 58.52 ± 30.56 42.05 ± 30.72 0.05
 Diastolic 64.98 ± 25.22 71.54 ± 22.28 0.35
Cholesterol, mg/dL 156.38 ± 31.33 164.93 ± 39.51 0.34
HDL cholesterol, mg/dL 37.8 ± 9.4 39.0 ± 8.8 0.63
LDL cholesterol, mg/dL 96.3 ± 25.1 100.4 ± 32.8 0.56
Non-HDL cholesterol, mg/dL 118.5 ± 30.0 125.6 ± 36.3 0.41
Triglycerides, mg/dL 112.8 ± 74.9 112.2 ± 56.7 0.97
ALT, U/L 24.3 ± 14.2 25.6 ± 9.8 0.72
AST, U/L 25.1 ± 16.1 24.2 ± 6.0 0.83
HbA1c, % 5.60 ± 0.43 5.57 ± 0.27 0.78
Fasting glucose, mg/dL 95.3 ± 12.0 94.0 ± 7.4 0.68
Fasting insulin, μU/mL 24.8 ± 15.5 34.9 ± 32.6 0.03
HOMA-IR 5.89 ± 4.01 8.28 ± 7.80 0.04
Data are expressed as mean ± standard deviation.
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